Department of Joint Surgery, the Fourth People's Hospital of Jinan, Jinan, China.
Department of Orthopedic Surgery, the Fourth People's Hospital of Jinan, Jinan, China.
Clinics (Sao Paulo). 2021 Jan 20;76:e1907. doi: 10.6061/clinics/2021/e1907. eCollection 2021.
This study was designed to evaluate the clinical efficacy of controlled-release morphine tablets combined with celecoxib in relieving osteocarcinoma-related pain and the effects of the combination on WNK1 expression.
A total of 110 patients with osteocarcinoma-related pain were selected and divided into two groups based on the treatment administered, including the control group (treated with controlled-release morphine tablets alone) and the study group (treated with a combination of controlled-release morphine tablets and celecoxib). We compared the treatment efficacy, pain level (visual analog scale (VAS)), time of onset of breakthrough pain (BTP), dose of morphine, incidence of adverse events, quality of life (QOL) score, and With-no-lysine 1 (WNK1) expression in the peripheral blood (PB) as determined with qRT-PCR before and after treatment, of the two groups.
The total effective rate of the study group was higher than that of the control group, while the VAS score, time of onset of BTP, dose of morphine, incidence of adverse events, QOL score, and relative WNK1 expression in the PB were lower than those of the control group (p<0.05).
Combination treatment with controlled-release morphine tablets and celecoxib can be extensively used in the clinical setting because it effectively improves the symptoms, QOL score, and adverse effects in patients with osteocarcinoma-related pain.
本研究旨在评估控释吗啡片联合塞来昔布治疗癌性骨痛的临床疗效及对丝氨酸苏氨酸激酶 1（WNK1）表达的影响。
选取 110 例癌性骨痛患者，根据治疗方法分为两组，对照组（单独给予控释吗啡片治疗）和观察组（给予控释吗啡片联合塞来昔布治疗）。比较两组患者的治疗效果、疼痛程度（视觉模拟评分法（VAS））、爆发性疼痛（BTP）的出现时间、吗啡用量、不良反应发生率、生活质量（QOL）评分及治疗前后外周血（PB）WNK1 表达情况。
观察组总有效率高于对照组，VAS 评分、BTP 出现时间、吗啡用量、不良反应发生率、QOL 评分及 PB 中 WNK1 相对表达量均低于对照组（p<0.05）。
控释吗啡片联合塞来昔布治疗癌性骨痛能有效改善患者的症状、QOL 评分及不良反应，可广泛应用于临床。
